Clinical trials: Midazolam
Healthy Volunteers
A Study to Assess the Effect of Cefiderocol on the Pharmacokinetics (PK) of Midazolam in Healthy Participants
The purpose of this study is to determine the effect of repeated doses of cefiderocol on the PK of midazolam.
- Trial name
- NCT05395104
- Testing
- Midazolam, Cefiderocol
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Shionogi
Epilepsy
Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU
This study is designed to evaluate the efficacy, safety, and tolerability of USL261 compared with that of intranasal (IN) placebo for the treatment of intermittent bouts of increased seizure activity.
- Trial name
- NCT01999777
- Testing
- USL261
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 62 people
- Sponsor
- UCB Biopharma S.P.R.L.
Colonoscopy
Safety and Efficacy of Remimazolam in ASA III and IV Patients Undergoing Colonoscopy
A prospective, double-blind, randomized, placebo and active controlled, multi-center, parallel group study comparing remimazolam to placebo, with an additional open-label arm for midazolam, in American Society of…
- Trial name
- NCT02532647
- Testing
- Remimazolam, Midazolam
- Where
- 3 sites in United States
- Volunteers
- 79 people
- Sponsor
- Paion UK Ltd.
Solid Cancers, Non-Hodgkin's Lymphoma
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
This is an open-label, multicenter, Phase I/II study to assess the safety, tolerability, and pharmacokinetics of GDC-0032. The Phase I portion will be divided into two stages.
- Trial name
- NCT01296555
- Testing
- Fulvestrant, GDC-0032, Letrozole
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 674 people
- Sponsor
- Genentech, Inc.
Relapsing-Remitting Multiple Sclerosis
An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis
The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants…
- Trial name
- OBSERVE (NCT01462318)
- Testing
- Midazolam, Caffeine, S-warfarin
- Where
- 19 sites in United States, Czechia and 2 more
- Volunteers
- 133 people
- Sponsor
- Biogen
Hepatitis B, Chronic
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of RO7049389 in Healthy Volunteers and Chronic Hepatitis B Virus (HBV) Infected Participants
This study is a multicenter, three-part study. Parts 1 and 2 are randomized, investigator- and participant-blinded, placebo-control, single-ascending dose (SAD) and multiple-ascending dose (MAD) study to evaluate the safety…
- Trial name
- NCT02952924
- Testing
- Midazolam, RO7049389
- Where
- 21 sites in Australia, Bulgaria and 6 more
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Arthroscopy, Bunionectomy
A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Minor Surgical Procedures
The purpose of this study is to determine the safety, tolerability, and efficacy of AQUAVAN® Injection when used for mild-to-moderate sedation in patients undergoing minor surgical procedures.
- Conditions
- Arthroscopy, Bunionectomy, Osteotomy, Carpal Tunnel
- Trial name
- NCT00209560
- Testing
- fospropofol disodium
- Volunteers
- 168 people
- Sponsor
- Eisai Inc.
Autistic Disorder, Autism Spectrum Disorder
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
This study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single- and multiple-ascending doses (SAD (Part 1) and MAD (Part 2)) and food effect (FE) of RO6953958 following oral…
- Conditions
- Autistic Disorder, Autism Spectrum Disorder, Child Development Disorders, Pervasive, Mental Disorders
- Trial name
- NCT04475848
- Testing
- RO6953958, Midazolam
- Where
- United Kingdom
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Sickle Cell Disease
Voxelotor CYP and Transporter Cocktail Interaction Study
This research study is examining multiple doses of voxelotor (a study drug intended for treatment of sickle cell disease) and how it interacts with additional substrates (substrates are drugs or other substances that are…
- Trial name
- NCT05981365
- Testing
- Voxelotor, Bupropion, Repaglinide
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
A Study to Test How Different Doses of BI 3731579 Are Tolerated by Healthy People
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics and pharmacodynamics of BI 3731579 in healthy volunteers following administration of multiple rising doses per day over 15 days.
- Trial name
- NCT06716190
- Testing
- Mid-dose bid BI 3731579, Midazolam, Low-dose bid BI 3731579
- Where
- Belgium
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Transplant Rejection
Study to Evaluate Effect of Belatacept on Pharmacokinetics of Inje Cocktail in Healthy Volunteers
The purpose of this study is to determine the effects of belatacept on the pharmacokinetics of caffeine, losartan, omeprazole, dextromethorphan and midazolam
- Trial name
- NCT01766050
- Testing
- Caffeine, Losartan, Omeprazole
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
A Study of LY3522348 in Healthy Participants
The main purpose of this study in healthy participants is to learn more about the safety of LY3522348 and any side effects that might be associated with it.
- Trial name
- NCT04559568
- Testing
- LY3522348, Midazolam
- Where
- United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy Volunteers
Open-label Study to Evaluate the Effects of NST-1024 on the PK of Multiple Drugs in Healthy Subjects
Phase 1, open label study to evaluate the effects of NST-1024 on the pharmacokinetics (PK) of caffeine (and paraxanthine), flurbiprofen, omeprazole, metoprolol, and midazolam (and 1-hydroxymidazolam) in healthy male and female…
- Trial name
- NCT05368831
- Testing
- NST-1024
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- NorthSea Therapeutics B.V.
Healthy Adults
STUDY TO EVALUATE THE EFFECT OF PF-06882961 ON SINGLE DOSE ATORVASTATIN, MEDAZOLAM AND ORALCONTRACEPTIVE PHARMACOKINETICS IN HEALTHY ADULT PARTICIPANTS
The purpose of this study is to characterize the effect of PF-06882961, administered at 2 steady-state dose levels, on the PK of single doses of atorvastatin (20 mg) or midazolam (5 mg), administered separately, in healthy adult…
- Trial name
- NCT05093205
- Testing
- PF-06882961, Atorvastatin, Midazolam
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis
A Study of Mirikizumab in Participants With Plaque Psoriasis
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the…
- Trial name
- NCT03718884
- Testing
- Drug Cocktail, Mirikizumab
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Electroencephalographic Neonatal Seizures
A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures
The purpose of the study is to evaluate the pharmacokinetics (PK) of brivaracetam (BRV) in neonates who have seizures that are not adequately controlled with previous antiepileptic drug (AED) treatment, and to identify the…
- Trial name
- NCT03325439
- Testing
- Brivaracetam (BRV) intravenous (iv), Brivaracetam (BRV) oral
- Where
- 12 sites in Belgium, Czechia and 5 more
- Volunteers
- 9 people
- Sponsor
- UCB Biopharma SRL
Healthy
A Study in Healthy Men to Test Whether BI 425809 Influences the Amount of Midazolam in the Blood
In order to assess the potential impact of steady state BI 425809 on CYP3A clinically, the effect of BI 425809 on the midazolam pharmacokinetics will be evaluated. Midazolam is a recommended substrate of CYP3A4.
- Trial name
- NCT05258110
- Testing
- midazolam, iclepertin (BI 425809)
- Where
- Germany
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Solid Tumor
Study of Cobimetinib in Participants With Solid Tumors
This non-randomized, open-label, study will determine the highest safe dose of cobimetinib, how often it should be taken, how well participants with cancer tolerate cobimetinib and will assess the pharmacokinetic effect of…
- Trial name
- NCT00467779
- Testing
- cobimetinib, dextromethorphan, midazolam
- Where
- 4 sites in United States
- Volunteers
- 119 people
- Sponsor
- Genentech, Inc.
Healthy
A Study in Healthy People to Test Whether BI 730357 Influences the Amount of Caffeine, Warfarin, Omeprazole, and Midazolam in the Blood
The trial will be performed to assess the influence of BI 730357 on the pharmacokinetics of caffeine, warfarin, omeprazole and midazolam.
- Trial name
- NCT04679948
- Testing
- Percoffedrinol®, Coumadin®, Antra MUPS®
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Nervous System Diseases
Study of Midazolam Hydrochloride Oromucosal Solution (MHOS/SHP615) in Pediatric Patients With Status Epilepticus (Convulsive) in the Community Setting
The purpose of this study is to determine if the investigational treatment, MHOS/SHP615, is safe and effective in children with status epilepticus (SE) (convulsive) in the community setting.
- Trial name
- NCT03336450
- Testing
- SHP615, MHOS/SHP615
- Where
- 23 sites in Japan
- Volunteers
- 3 people
- Sponsor
- Shire